The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Difficult to buy this morning 20k shares and 16k shares.
Donmac thanks to let me know about results in two weeks, give me a chance to top up..if news on result is that they opening for commercial stage...well like to know its value?
Great Potential,Strong progress on rollout strategy
In line with its strategic plan, the Company is working with three leading US transplant centres in the Tutivia (TM) commercial launch and is supporting them with the adoption and integration of the test into the current clinical pathway, to encourage consistent and recurring utilisation. This is providing a valuable foundation for Verici Dx to make Tutivia(TM) as simple as possible for clinicians to use and interpret...Multiple from here..80P
Patience...the JV with Chemx is due with us to enable successful of Lithium..news was due mid April or May and Tesla pulling strings all involved in Bolivia....on success a 100 bagger for CLON and miracle for the country...Imo
MediMan no not into chatrs..though this three weeks has been frustrating...modest holding showing £5k down as with Ciz avoiding trading...I will to the bitter end...well if it has woken Gdr from 11 to 42 in 12 weeks..it can happen here to 12....and 30p if its green light from Corepath byJune and more if China LDT is positive...all wishful thinking..all have a good weekend..
Condiut merger will be sooner than later,most importantly waitinng for Validation update from Corepath. we can move forward on positive report hence Ciz will have access to 22 states with China to look forward to so taking in
assumption that the Cizzle Biotechnology test would cost the NHS £200 (for comparison, a PSA tests costs
£100, and a breast genetic/biomarker test costs £600, and a chest CT scan costs £400), the UK market
potential is £20.7 million p.a. Removing 50 per cent. of the false positives from two-year follow-up would
result in 207,400 fewer chest CT scans being performed, saving the NHS £83.0m, generating net savings
of £62.3 million over a two-year period for the NHS